Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell...

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Hypoxia-inducible factor (HIF) regulates gene expression and cellular processes.
• Constitutive HIF-1alpha stabilization is observed in most diffuse large B-cell lymphoma (DLBCL) cases.
• The prognostic value of HIF in lymphoma has not been previously established.

Purpose of the Study:

• To investigate the prognostic significance of HIF-1alpha protein expression in DLBCL patients.
• To correlate HIF-1alpha expression with patient outcomes following CHOP or R-CHOP chemotherapy.

Main Methods:

• Immunohistochemical analysis of HIF-1alpha protein expression on tissue microarrays from 153 DLBCL patients.
• Patients were treated with cyclophosphamide, doxorubicin, oncovin, and prednisone (CHOP) or rituximab-CHOP (R-CHOP) between 1999 and 2002.
• Outcomes, including progression-free survival (PFS) and overall survival (OS), were correlated with HIF-1alpha expression.

Main Results:

• HIF-1alpha was expressed in 62% of germinal center and 59% of non-germinal center DLBCL patients.
• In the R-CHOP treated cohort, HIF-1alpha expression significantly correlated with improved PFS and OS.
• Five-year PFS was 71% for HIF-1alpha-positive vs. 43% for negative patients (P = .0187); 5-year OS was 75% vs. 54% (P = .025).
• HIF-1alpha remained an independent predictor for PFS and OS in multivariate analysis, correlating only with BCL6 expression.

Conclusions:

• HIF-1alpha protein expression is a significant independent favorable prognostic factor in DLBCL patients treated with R-CHOP.
• HIF-1alpha positivity is associated with substantially improved progression-free and overall survival.
• Further research may explore targeting HIF pathways in DLBCL treatment strategies.